Is it safe to give the inactivated influenza vaccine to a healthy 40-year-old woman using Kenogel (clobetasol propionate 0.05% topical cream)?

Recommendation

Yes — administer the inactivated influenza vaccine routinely; concurrent use of topical clobetasol (Kenogel/clobetasol 0.05%) is not a contraindication and does not meaningfully affect morbidity, mortality, or quality of life outcomes from influenza vaccination. 1

Rationale (prioritized by strongest, most recent guideline)

• 2024–25 ACIP: All adults ≥6 months should receive age-appropriate inactivated influenza vaccine (IIV); contraindications relate to severe allergy to vaccine components, not to use of topical corticosteroids. LAIV is limited to ages 2–49 and avoided only around severely immunocompromised contacts; this does not apply here. Topical steroids are not considered systemic immunosuppression for vaccine decisions. 1

Practical algorithm

• If age 40, healthy, using topical clobetasol:
  • Give standard-dose IIV (0.5 mL IM) now. 1
  • Avoid LAIV only if she will have close contact with severely immunocompromised patients in protective environments; otherwise either IIV or LAIV would be acceptable by ACIP age criteria, but IIV is simplest. 1
• Screen only for:
  • History of severe allergic reaction to prior influenza vaccine or its components → if present, choose an appropriate alternative or refer. 1
  • Moderate/severe acute illness with fever → defer until improved. [General ACIP principles reflected across MMWR history: 1, earlier precedent 2,3]

Nuances and pitfalls

• Topical clobetasol:
  • High-potency topical steroids can cause systemic absorption if applied over large BSA/occlusion, but ACIP does not classify topical use as an immunosuppressive contraindication to IIV; no adjustment to influenza vaccination is recommended. [General vaccine guidance; ACIP 2024: 1]
• Do not delay vaccination for minor illnesses; proceed unless severely ill. 1
• For mortality and QOL: IIV reduces severe influenza outcomes with acceptable safety in healthy adults. [Augmented by adult RCT safety/benefit data: 4]

What to avoid

• Do not withhold IIV because of topical steroid use—this is a common, unnecessary delay. 1
• Do not choose LAIV if she will have contact with severely immunocompromised persons in protected environments within 7 days after vaccination. If LAIV is used, avoid such contact for 7 days. 1